Literature DB >> 12819840

Real-time RT-PCR methodology for quantification of thiopurine methyltransferase gene expression.

Malin Lindqvist1, Sven Almer, Curt Peterson, Peter Söderkvist.   

Abstract

OBJECTIVE: The aim of the present study was to develop a real-time reverse-transcription polymerase chain reaction (RT-PCR) methodology for the quantification of thiopurine methyltransferase (TPMT) gene expression in whole blood and compare it with the TPMT enzyme activity measured in red blood cells.
METHODS: TPMT gene expression was quantified relative to the housekeeping gene cyclophilin (huCYC) and expressed as a TPMT/huCYC ratio. TPMT activity in red blood cells was determined by measuring the formation rate of 6-(14)C-methylmercaptopurine from 6-MP using S-adenosyl-L-((14)C-methyl)-methionine as methyl donor. Thirty-nine individuals were included in the study. A cut-off value of 9 U/ml pRBC was used to distinguish intermediate TPMT enzyme activity from high TPMT enzyme activity.
RESULTS: Sequencing of the real-time RT-PCR amplicon proved that the method was specific for the TPMT cDNA, without co-amplification of the highly similar TPMT processed pseudogene. The intra-assay coefficients of variation (CVs), as determined by the threshold cycle, were 0.7% for TPMT and 0.5% for huCYC. The interassay CVs were 1.5% for TPMT and 4.0% for huCYC. The intra- and interassay CVs, as determined by the TPMT/huCYC ratio, were 8.6% and 25%, respectively. There was a statistically significant correlation between TPMT enzyme activity and mRNA level in blood cells from individuals with an enzyme activity above 9 U/ml pRBC (r(s)=0.66, P=0.0001). However, we did not find any statistically significant correlation in individuals with lower enzyme activity or when analysing the whole population.
CONCLUSION: We present a specific and robust real-time RT-PCR method for quantifying TPMT gene expression. The method may be used for studies on TPMT gene regulation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12819840     DOI: 10.1007/s00228-003-0617-z

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  21 in total

1.  Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMT*3B or TPMT*3C.

Authors:  H L Tai; M Y Fessing; E J Bonten; Y Yanishevsky; A d'Azzo; E Y Krynetski; W E Evans
Journal:  Pharmacogenetics       Date:  1999-10

Review 2.  Pharmacogenetics of cancer therapy: getting personal.

Authors:  E Y Krynetski; W E Evans
Journal:  Am J Hum Genet       Date:  1998-07       Impact factor: 11.025

3.  Real time quantitative PCR.

Authors:  C A Heid; J Stevens; K J Livak; P M Williams
Journal:  Genome Res       Date:  1996-10       Impact factor: 9.043

4.  Human thiopurine methyltransferase pharmacogenetics. Kindred with a terminal exon splice junction mutation that results in loss of activity.

Authors:  D M Otterness; C L Szumlanski; T C Wood; R M Weinshilboum
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

5.  Influence of the variable number of tandem repeats located in the promoter region of the thiopurine methyltransferase gene on enzymatic activity.

Authors:  S Alves; A Amorim; F Ferreira; M J Prata
Journal:  Clin Pharmacol Ther       Date:  2001-08       Impact factor: 6.875

6.  Thiopurine methyltransferase pharmacogenetics: alternative molecular diagnosis and preliminary data from Northern Portugal.

Authors:  S Alves; M J Prata; F Ferreira; A Amorim
Journal:  Pharmacogenetics       Date:  1999-04

7.  Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians.

Authors:  H L Tai; E Y Krynetski; C R Yates; T Loennechen; M Y Fessing; N F Krynetskaia; W E Evans
Journal:  Am J Hum Genet       Date:  1996-04       Impact factor: 11.025

8.  Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity.

Authors:  R M Weinshilboum; S L Sladek
Journal:  Am J Hum Genet       Date:  1980-09       Impact factor: 11.025

9.  A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase.

Authors:  E Y Krynetski; J D Schuetz; A J Galpin; C H Pui; M V Relling; W E Evans
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-14       Impact factor: 11.205

10.  Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia.

Authors:  W E Evans; M Horner; Y Q Chu; D Kalwinsky; W M Roberts
Journal:  J Pediatr       Date:  1991-12       Impact factor: 4.406

View more
  3 in total

Review 1.  Polymorphic variation in TPMT is the principal determinant of TPMT phenotype: A meta-analysis of three genome-wide association studies.

Authors:  R Tamm; R Mägi; R Tremmel; S Winter; E Mihailov; A Smid; A Möricke; K Klein; M Schrappe; M Stanulla; R Houlston; R Weinshilboum; Irena Mlinarič Raščan; A Metspalu; L Milani; M Schwab; E Schaeffeler
Journal:  Clin Pharmacol Ther       Date:  2017-02-01       Impact factor: 6.875

Review 2.  The thiopurines: an update.

Authors:  Sally Coulthard; Linda Hogarth
Journal:  Invest New Drugs       Date:  2005-12       Impact factor: 3.850

3.  Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease.

Authors:  U Hindorf; M Lindqvist; C Peterson; P Söderkvist; M Ström; H Hjortswang; A Pousette; S Almer
Journal:  Gut       Date:  2006-03-16       Impact factor: 23.059

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.